Norepinephrine Sopharma (Noradrenaline Tartrate)

Norepinephrine, the active ingredient in Norepinephrine Sopharma, is a sympathomimetic agent presented as an injectable solution for intravenous use. It acts as a potent vasopressor to raise blood pressure in patients experiencing hypotension, septic shock, or cardiac arrest.

GNH USA supplies Norepinephrine Sopharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution. Our network ensures timely delivery and regulatory compliance.

Norepinephrine is a sympathomimetic vasopressor used in critical care to support circulatory function.

- Hypotension: restores arterial pressure and improves organ perfusion in acute low‑blood‑pressure states. - Septic shock: counteracts vasodilatory shock by increasing systemic vascular resistance and maintaining mean arterial pressure. - Cardiac arrest: provides immediate pressor support during resuscitation to enhance coronary and cerebral blood flow.

Norepinephrine may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Tachycardia: increased heart rate. - Palpitations: sensation of rapid or irregular heartbeat. - Anxiety or restlessness. - Nausea or vomiting. - Peripheral ischemia: reduced blood flow to extremities causing coldness or discoloration.

Serious or Rare Side Effects: - Cardiac arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: chest pain due to reduced coronary perfusion. - Severe hypertension: dangerously high blood pressure. - Tissue necrosis at infusion site. - Pulmonary edema: fluid accumulation in lungs. - Reflex bradycardia: paradoxical slowing of heart rate.

When using norepinephrine, clinicians should observe several precautions to minimize risks and ensure safe administration.

- Dose titration: adjust infusion rate based on continuous blood pressure monitoring. - Cardiac monitoring: observe for arrhythmias and ischemia during therapy. - Extravasation risk: avoid infiltration; use central venous access when possible. - Concomitant vasopressors: limit simultaneous use to prevent excessive vasoconstriction. - Patient selection: avoid in patients with uncontrolled hypertension or severe peripheral vascular disease. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Norepinephrine can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - β‑blockers: may blunt β1‑mediated cardiac effects, reducing desired increase in cardiac output. - MAO inhibitors: can potentiate hypertensive response. - Tricyclic antidepressants: increase risk of severe hypertension.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: additive vasodilatory effects may require dose adjustment. - Diuretics: volume depletion can enhance hypotensive episodes if norepinephrine is tapered. - Inhaled anesthetics: may modify vascular response, necessitating close hemodynamic monitoring.